Company Filing History:
Years Active: 2006
Title: Innovations of Anders Sundan in Antibody Development
Introduction
Anders Sundan is a notable inventor based in Trondheim, Norway. He has made significant contributions to the field of immunology, particularly through his innovative work on antibodies. His research focuses on the human toll-like receptor 2 (TLR2) and its implications in treating bacterial infections.
Latest Patents
Anders Sundan holds a patent for an "Antibody against the human toll-like receptor 2 (TLR2) and uses thereof." This invention relates to an antibody capable of binding to human TLR2, which specifically binds only to CD14 cells in a normal human mononuclear cell population, while not binding to CD14 cells. Importantly, this antibody does not inhibit LPS-induced activation of normal human mononuclear cells. The applications of this invention are particularly relevant in the treatment of bacterial infections mediated via the TLR2 receptor, especially bacterial sepsis. Additionally, the antibodies serve as a general research tool for screening TLR2 expression and studying TLR2 function.
Career Highlights
Anders Sundan is associated with Leiv Eiriksson Nyskaping AS, where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on therapeutic strategies against bacterial infections.
Collaborations
Anders collaborates with Terje Espevik, enhancing the research capabilities and broadening the scope of their innovative projects.
Conclusion
Anders Sundan's contributions to antibody development represent a significant advancement in immunological research. His innovative patent on TLR2 antibodies showcases the potential for new treatments in combating bacterial infections.